PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers

PRIMAGE is one of the largest and more ambitious research projects dealing with medical imaging, artificial intelligence and cancer treatment in children. It is a 4-year European Commission-financed project that has 16 European partners in the consortium, including the European Society for Paediatric Oncology, two imaging biobanks, and three prominent European paediatric oncology units. The project is constructed as an observational in silico study involving high-quality anonymised datasets (imaging, clinical, molecular, and genetics) for the training and validation of machine learning and multiscale algorithms. The open cloud-based platform will offer precise clinical assistance for phenotyping (diagnosis), treatment allocation (prediction), and patient endpoints (prognosis), based on the use of imaging biomarkers, tumour growth simulation, advanced visualisation of confidence scores, and machine-learning approaches. The decision support prototype will be constructed and validated on two paediatric cancers: neuroblastoma and diffuse intrinsic pontine glioma. External validation will be performed on data recruited from independent collaborative centres. Final results will be available for the scientific community at the end of the project, and ready for translation to other malignant solid tumours.

[1]  Marian Bubak,et al.  Cloud computing infrastructure for the VPH community , 2017, J. Comput. Sci..

[2]  James M Robins,et al.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.

[3]  Stuart A. Taylor,et al.  Imaging biomarker roadmap for cancer studies , 2016, Nature Reviews Clinical Oncology.

[4]  Ruth Ladenstein,et al.  Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[5]  Michaël Lauer,et al.  Book Review Redefining Health Care: Creating Value-Based Competition on Results By Michael E. Porter and Elizabeth Olmsted Teisberg. 506 pp. Boston, Harvard Business School Press, 2006. $35. 978-1-59139-778-6 , 2006 .

[6]  Vikas Prasad,et al.  2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors , 2017, Klinische Pädiatrie.

[7]  Luis Martí-Bonmatí,et al.  Imaging Biomarkers and Imaging Biobanks , 2019, Artificial Intelligence in Medical Imaging.

[8]  Alejandro F. Frangi,et al.  Support for Taverna workflows in the VPH-Share cloud platform , 2017, Comput. Methods Programs Biomed..

[9]  Giovanni Cecchetto,et al.  Influence of image‐defined risk factors on the outcome of patients with localised neuroblastoma. A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group , 2015, Pediatric blood & cancer.

[10]  Barbara Hero,et al.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Martí-Bonmatí,et al.  How to integrate quantitative information into imaging reports for oncologic patients. , 2018, Radiologia.

[12]  Mohammed Ali Kazem,et al.  Predictive models in cancer management: A guide for clinicians. , 2017, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[13]  Marina Kolesnik,et al.  Go-Smart: Open-Ended, Web-Based Modelling of Minimally Invasive Cancer Treatments via a Clinical Domain Approach , 2018, ArXiv.

[14]  Günter Schreier,et al.  Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[15]  Olaf Klungel,et al.  Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  G. García-Martí,et al.  [Imaging biomarkers, quantitative imaging, and bioengineering]. , 2012 .

[17]  M. Chaplain,et al.  Mathematical modeling of tumor growth and treatment. , 2014, Current pharmaceutical design.

[18]  Ruth Ladenstein,et al.  Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Martí Bonmatí,et al.  [Imaging biomarkers, quantitative imaging, and bioengineering]. , 2012, Radiologia.

[20]  Andrey Brito,et al.  ATMOSPHERE: Adaptive, Trustworthy, Manageable, Orchestrated, Secure, Privacy-Assuring, Hybrid Ecosystem for Resilient Cloud Computing , 2019, 2019 9th Latin-American Symposium on Dependable Computing (LADC).

[21]  Ruth Ladenstein,et al.  Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Ruth Ladenstein,et al.  Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Sushmita N Bhatnagar An Audit of Malignant Solid Tumors in Infants and Neonates , 2012, Journal of neonatal surgery.

[24]  Gary E. Day,et al.  Redefining Health Care: Creating Value-Based Competition on Results , 2006 .

[25]  C. A. Howell,et al.  An integrated occupancy and space‐use model to predict abundance of imperfectly detected, territorial vertebrates , 2016 .

[26]  Marco Viceconti,et al.  In silico clinical trials: how computer simulation will transform the biomedical industry , 2016 .

[27]  Daniela M. Romano,et al.  High performance cellular level agent-based simulation with FLAME for the GPU , 2010, Briefings Bioinform..

[28]  M. de Jong,et al.  Biomarkers in preclinical cancer imaging , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  Bernard M. Corfe,et al.  An agent-based model of anoikis in the colon crypt displays novel emergent behaviour consistent with biological observations , 2017, Royal Society Open Science.

[30]  Michelle Monje,et al.  Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets , 2016, Current neuropharmacology.

[31]  L Martí-Bonmatí,et al.  How to integrate quantitative information into imaging reports for oncologic patients. , 2018, Radiologia.

[32]  Giovanni Cecchetto,et al.  Image‐defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy‐induced variation, and impact on surgical outcomes , 2017, Pediatric blood & cancer.

[33]  Roger D. Kamm,et al.  Balance of mechanical forces drives endothelial gap formation and may facilitate cancer and immune-cell extravasation , 2018, bioRxiv.

[34]  K K Matthay,et al.  Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[36]  Andrey Brito,et al.  ATMOSPHERE: Adaptive, Trustworthy, Manageable, Orchestrated, Secure, Privacy-Assuring, Hybrid Ecosystem for REsilient Cloud Computing , 2018, 2018 48th Annual IEEE/IFIP International Conference on Dependable Systems and Networks Workshops (DSN-W).

[37]  A Garaventa,et al.  Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study. , 2013, European journal of cancer.

[38]  Daniel A. Keim,et al.  Knowledge Generation Model for Visual Analytics , 2014, IEEE Transactions on Visualization and Computer Graphics.

[39]  Ruth Ladenstein,et al.  Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study , 2018, Pediatric blood & cancer.